Pareto Biotechnologies featured in SynBioBeta’s first industry report
SynBioBeta brought out a new service to the synthetic biology community: industry reports. And the first company they have chosen to feature is our very own Pareto Biotechnologies. The report is free:
SynBioBeta is offering all of our readers the full Pareto Biotechnologies write-up for free! For the remainder of the content, we have decided on a competitive pricing model for both the full report and individual company reports — allowing everyone to access our broad network and high-quality research.
We enjoyed the engaging style of the report — the photos of Pareto’s “brain trust” are awesome — and it provides a lot of good information about the history of the field and Pareto’s role in it.
The intellectual property position and brain trust of Pareto Biotechnologies is unparalleled to other startups at its stage of development, which reduces the risks presented by business and technology development. Pathways being developed by the company are unique to them — which means few, if any, companies are targeting the same or similar class of molecules at the moment. Additionally, risk is further reduced by the initial pursuit of high value molecules that require demonstrably less development and capital than mass market molecules.
We also appreciated the kind words about our program:
Focusing on getting culture right from the beginning will pay huge dividends in the future — and so does having access to a great network. When Pareto Biotechnologies was awarded a $350,000 grant from Peter Thiel’s Breakout Labs, the company earned more than funding. The team received an instant boost in credibility and awareness for its work, gained access to a network of investors and venture capitalists, and broke into the Breakout Labs network of entrepreneurs. The latter is especially important in the eyes of Bacher. “You want to find friends and colleagues that are also founders and CEOs who would want your company to succeed. It is empowering.”
This promises to be a great service for entrepreneurs, investors, enthusiasts, and even skeptics in the synthetic biology community.
